Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol for Prevention of Conversion From MCI to Dementia
NCT02491268Phase 2Completed
- Sponsor
- National Cerebral and Cardiovascular Center
- Start
- May 2015
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cilostazol in Mild Cognitive Impairment (MCI), sponsored by National Cerebral and Cardiovascular Center. Started May 2015; status: completed.
02
Drugs
cilostazol
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT02491268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02491268.